<?xml version="1.0" encoding="UTF-8"?>
<ref id="pds5133-bib-0025">
 <label>25</label>
 <mixed-citation publication-type="miscellaneous" id="pds5133-cit-0025">Direct Healthcare Professional Communication Restrictions on the use of Zydelig®▼ (idelalisib) for the treatment of chronic lymphocytic leukaemia (CLL) and relapsed follicular lymphoma (FL) following new clinical trial results. 
  <ext-link ext-link-type="uri" xlink:href="https://assets.publishing.service.gov.uk/media/5707baba40f0b60385000056/Zydelig__idelalisib__-_DHPC_sent_23_03_2016.pdf" xmlns:xlink="http://www.w3.org/1999/xlink">https://assets.publishing.service.gov.uk/media/5707baba40f0b60385000056/Zydelig__idelalisib__‐_DHPC_sent_23_03_2016.pdf</ext-link>. Accessed November 8, 2019.
 </mixed-citation>
</ref>
